Nanox.ARC Gets FDA Clearance for Expanded Diagnostic Imaging
By Daniella
Nanox (Nasdaq: NNOX), received FDA clearance to produce tomographic images for broader diagnostic applications, the company said.
Nanox.ARC, now deployed in healthcare facilities across seven U.S. states, utilize proprietary tomosynthesis technology with a cold cathode, the system delivers detailed 3D imaging, improving visualization and reducing limitations of traditional 2D X-rays, the company said.
“With this FDA clearance, we can now offer U.S. healthcare providers significantly broader imaging capabilities that are akin to commonly used traditional X-ray devices,” said Erez Meltzer, Nanox Chief Executive Officer and Acting Chairman. “Our mission is to provide healthcare practices with a transformative imaging advantage with the Nanox.ARC – an accessible, cost-effective solution that not only provides advanced diagnostic imaging capabilities but also elevates overall patient care.”
Contact:
Editor@executives-edge.com
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Most Discussed
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10